Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaveloxolone PK in Hepatic Impairment
NCT03902002Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omaveloxolone in Friedreich's ataxia (FA) (4 arms), sponsored by Biogen. Primary endpoints: Maximum concentration (Cmax) of omaveloxolone in plasma at 15 days and Area under the plasma omaveloxolone concentration-time curve (AUC) at 15 days. Started Jul 2019; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT03902002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902002.